Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Whole-genome analysis approaches are identifying recurrent cancer-associated somatic alterations in noncoding DNA regions. We combined somatic copy number analysis of 12 tumor types with tissue-specific epigenetic profiling to identify significant regions of focal amplification harboring super-enhancers. Copy number gains of noncoding regions harboring super-enhancers near
KLF5
, USP12, PARD6B and MYC are associated with overexpression of these cancer-related genes. We show that two distinct focal amplifications of super-enhancers 3' to MYC in lung adenocarcinoma (MYC-LASE) and
endometrial carcinoma
(MYC-ECSE) are physically associated with the MYC promoter and correlate with MYC overexpression. CRISPR/Cas9-mediated repression or deletion of a constituent enhancer within the MYC-LASE region led to significant reductions in the expression of MYC and its target genes and to the impairment of anchorage-independent and clonogenic growth, consistent with an oncogenic function. Our results suggest that genomic amplification of super-enhancers represents a common mechanism to activate cancer driver genes in multiple cancer types.
...
PMID:Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. 2665 44
We conducted a meta-analysis of three
endometrial cancer
genome-wide association studies (GWAS) and two follow-up phases totaling 7,737
endometrial cancer
cases and 37,144 controls of European ancestry. Genome-wide imputation and meta-analysis identified five new risk loci of genome-wide significance at likely regulatory regions on chromosomes 13q22.1 (rs11841589, near
KLF5
), 6q22.31 (rs13328298, in LOC643623 and near HEY2 and NCOA7), 8q24.21 (rs4733613, telomeric to MYC), 15q15.1 (rs937213, in EIF2AK4, near BMF) and 14q32.33 (rs2498796, in AKT1, near SIVA1). We also found a second independent 8q24.21 signal (rs17232730). Functional studies of the 13q22.1 locus showed that rs9600103 (pairwise r(2) = 0.98 with rs11841589) is located in a region of active chromatin that interacts with the
KLF5
promoter region. The rs9600103[T] allele that is protective in
endometrial cancer
suppressed gene expression in vitro, suggesting that regulation of the expression of
KLF5
, a gene linked to uterine development, is implicated in tumorigenesis. These findings provide enhanced insight into the genetic and biological basis of
endometrial cancer
.
...
PMID:Five endometrial cancer risk loci identified through genome-wide association analysis. 2713 1
Objective:
Long noncoding RNA urothelial carcinoma associated 1 (
UCA1
) was found to facilitate
endometrial cancer
cell metastasis, and high
UCA1
expression predicted
endometrial cancer
development and patients' worsened outcomes. This research aimed to investigate the cancer promoting role and mechanism of
UCA1
in
endometrial cancer
.
Materials and Methods:
Around 64 endometrioid adenocarcinoma patients' tissue specimens were analyzed by qRT-PCR. Primary
endometrial cancer
cell culture was established
in vitro
.
UCA1
overexpression or knockdown was executed by adenoviral transduction. Cell proliferation, apoptosis, colony formation, transwell invasion, and epithelia-to-mesenchymal transition of primary
endometrial cancer
cells were assessed. Interactions among
UCA1
, microRNAs (miRNAs), and mRNAs were investigated by luciferase reporter assay and argonaute 2 (AGO2)-RNA immunoprecipitation. Nude mouse xenograft assay was used to explore the role of
UCA1
in
endometrial cancer
in vivo
.
Results:
UCA1
was significantly upregulated in
endometrial cancer
tissues compared to normal tissues. High expression of
UCA1
associated with
endometrial cancer
progression and patients' decreased survival. Overexpressing
UCA1
significantly increased the malignancy of primary
endometrial cancer
cells
in vitro
, while
UCA1
knockdown showed opposite effect. Kruppel-like factor 5 (
KLF5
) and relaxin like family peptide receptor 1 (
RXFP1
) were found as two
UCA1
co-expressing genes in
endometrial cancer
.
UCA1
increased the malignancy of endometrial cells partially through
KLF5
, and it increased the relaxin 2-induced
endometrial cancer
cell metastasis through RXFP1.
UCA1
reduced the si-RNA-induced silencing of
KLF5
and
RXFP1
genes in
endometrial cancer
cells.
MiR-143-3p
and
miR-1-3p
were found to interact with both
UCA1
and
KLF5
mRNA. In addition, knockdown of
UCA1
suppressed tumor growth in
endometrial cancer
in vivo
.
Conclusion:
UCA1
might facilitate
endometrial cancer
development by upregulating
KLF5
and
RXFP1
gene expression by sponging
miR-143-3p
and
miR-1-3p
.
...
PMID:Long Noncoding RNA
UCA1
Facilitates Endometrial Cancer Development by Regulating
KLF5
and
RXFP1
Gene Expressions. 3241 93